Author

Jean‐Louis Abitbol

Observed names: Abitbol Jean-Louis, J L Abitbol, J. -L. Abitbol, J. Abitbol, J. L. Abitbol, J.-L. Abitbol, J.L. Abitbol, Jean Louis Abitbol, Jean-Louis Abitbol

Institution: Inventiva (France)

Observed institutions: Cliniques Universitaires Saint-Luc, Université Libre de Bruxelles, University of Antwerp, Inserm, Virginia Commonwealth University, Tel Aviv Sourasky Medical Center, Northern General Hospital, Institut Gustave Roussy, University of California San Diego, Sorbonne Université, Antwerp University Hospital, Inventiva (France), Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Bichat-Claude-Bernard, HRA Pharma (France), Newcastle University, University of Sheffield, UCLouvain

ORCID: 0000-0002-3314-4727

Observed ORCID: 0000-0002-3314-4727

OpenAlex ID: A5112572041

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

2021 · Sven M. Francque, Pierre Bedossa, et al. · New England Journal of Medicine · 851

PDF

The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome

1999 · Michel Delvaux, Dominique Louvel, et al. · Gastroenterology · 159

PDF

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome: A multicenter dose-response study

1995 · M. Dapoigny, J. -L. Abitbol, et al. · Digestive Diseases and Sciences · 152

A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

2014 · T. Lenglet, L. Lacomblez, et al. · European Journal of Neurology · 136

Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound

2010 · Thierry Bordet, Patrick Berna, et al. · Pharmaceuticals · 127

PDF

Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

2017 · Enrico Bertini, Eric Dessaud, et al. · The Lancet Neurology · 122

PDF

Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD

2025 · Diana Barb, Srilaxmi Kalavalapalli, et al. · Journal of Hepatology · 108

Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion

2017 · Miguel Debono, Robert F Harrison, et al. · The Journal of Clinical Endocrinology & Metabolism · 106

PDF

Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia

1997 · N W Read, J L Abitbol, et al. · Gut · 106

PDF

Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception

2014 · Nathalie Kapp, Jean Louis Abitbol, et al. · Contraception · 95

Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy

2008 · Thierry Bordet, Bruno Buisson, et al. · Journal of Pharmacology and Experimental Therapeutics · 81

A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study

2020 · Francque Sven M., Bedossa Pierre, et al. · Contemporary Clinical Trials · 80

PDF

A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception

2015 · V. Brache, L. Cochon, et al. · Human Reproduction · 76

Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women

2014 · Delphine P. Levy, Martine Jager, et al. · Contraception · 72

Defining Survival as an Outcome Measure in Amyotrophic Lateral Sclerosis

2009 · Paul H. Gordon, Philippe Corcia, et al. · Archives of Neurology · 50

Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial

2014 · Sophie Le Lamer, Stéphanie Paradis, et al. · Journal of Translational Medicine · 36

PDF

Epithelial cell proliferation in the rectal stump of patients with ileorectal anastomosis for ulcerative colitis.

1983 · T Lehy, M Mignon, et al. · Gut · 27

PDF

Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment

2025 · Pierre-Emmanuel Rautou, Shivani Chotkoe, et al. · JHEP Reports · 17

PDF

Drug Discovery and Development for Spinal Muscular Atrophy: Lessons from Screening Approaches and Future Challenges for Clinical Development

2010 · Rebecca M Pruss, Marc Giraudon-Paoli, et al. · Future Medicinal Chemistry · 15

Oral treatment for mucopolysaccharidosis VI : Outcomes of the first phase IIa study with odiparcil

2021 · Nathalie Guffon, Pratima Chowdary, et al. · Journal of Inherited Metabolic Disease · 13

[Continuous ambulatory enteral feeding in hospitalized adults: prospective experience in 98 patients].

1986 · P Beau, J Fabre, et al. · PubMed · 10

[Influence of rectal preparation by enema on cell proliferation in the normal rectal mucosa in man].

1984 · T Lehy, J L Abitbol, et al. · PubMed · 10

Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis

2025 · Jérôme Boursier, Hugo Hervé, et al. · Clinical Gastroenterology and Hepatology · 7

Fedotozine in functional dyspepsia: Results of a 6 week placebo-controlled multicenter therapeutic trial

1995 · N.W. Read, K.D. Bardhan, et al. · Gastroenterology · 7

PDF

Fedotozine in irritable bowel syndrome: Results of a 6 wk placebo-controlled multicenter therapeutic trial

1995 · M. Dapoigny, J.L. Abitbol, et al. · Gastroenterology · 6

PDF

Works count: 42

Citation count: 2,491

H-index: 17

I10-index: 22